Injections from the GLP1 family contain a substance similar to the GLP1 hormone that has a multi-systemic effect on our body: it slows down the motility of the stomach, increases the sense of satiety, lowers blood sugar levels, reduces inflammatory processes and thus also leads not only to obesity but to a reduced risk of heart attacks and strokes. Recent reports also claim that these injections may even improve fertility in women.
The new study carried out between 2005 and 2018 compared the condition of type 2 diabetes patients (“adult diabetes”) who were treated with injections from the GLP1 family, including the “Ozmepic” injection, to diabetic patients who were treated only with insulin injections. The researchers found that those who received the GLP1 injections had a low risk Significant for having 10 of the 13 types of cancer studied, including kidney, pancreatic, esophageal, and colon cancer. These diseases are known to have a high incidence in those who are obese. Among the types of cancer in which no significant change in risk was observed was thyroid cancer and breast cancer in women.
“Obesity is known to be associated with at least 13 types of cancer,” the researchers said, “The study provides evidence that injections from the GLP1 family break the link between obesity and cancer, which may encourage doctors to prescribe these drugs for type 2 diabetes patients, instead of the insulin drugs.”